{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "regularMarketChangePercent": 1.1764686, "regularMarketPrice": 0.0086, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.01, "sharesOutstanding": 1056300032, "bookValue": 0.167, "fiftyDayAverage": 0.012762, "fiftyDayAverageChange": -0.0041619996, "fiftyDayAverageChangePercent": -0.3261244, "twoHundredDayAverage": 0.010213, "twoHundredDayAverageChange": -0.0016129995, "twoHundredDayAverageChangePercent": -0.15793592, "marketCap": 21050564, "priceToBook": 0.05149701, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1389596400000, "priceHint": 4, "marketState": "REGULAR", "exchange": "FRA", "shortName": "ABLIVA AB AK", "longName": "Abliva AB (publ)", "messageBoardId": "finmb_24193861", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChange": 9.999983e-05, "regularMarketTime": 1683892037, "regularMarketDayHigh": 0.0086, "regularMarketDayRange": "0.0082 - 0.0086", "regularMarketDayLow": 0.0082, "regularMarketVolume": 16000, "regularMarketPreviousClose": 0.0085, "bid": 0.0, "ask": 0.0, "bidSize": 16900, "askSize": 16300, "fullExchangeName": "Frankfurt", "financialCurrency": "SEK", "regularMarketOpen": 0.0082, "averageDailyVolume3Month": 542, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.0085, "fiftyTwoWeekLowChangePercent": 85.00001, "fiftyTwoWeekRange": "1.0E-4 - 0.0494", "fiftyTwoWeekHighChange": -0.0408, "fiftyTwoWeekHighChangePercent": -0.8259109, "fiftyTwoWeekLow": 0.0001, "fiftyTwoWeekHigh": 0.0494, "symbol": "NTP.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Medicon Village", "city": "Lund", "zip": "223 81", "country": "Sweden", "phone": "46 4 62 75 62 20", "website": "https://abliva.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.", "fullTimeEmployees": 6, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ellen K. Donnelly Ph.D.", "age": 48, "title": "Chief Exec. Officer", "yearBorn": 1974, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Catharina Jz Johansson", "age": 55, "title": "Deputy CEO, CFO & VP of Investor Relations", "yearBorn": 1967, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Eskil  Elm\u00e9r", "age": 52, "title": "Chief Scientific Officer & VP of Discovery", "yearBorn": 1970, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Daniel  Schale", "title": "Director of Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Magnus  Hansson", "age": 46, "title": "Chief Medical Officer and VP of Preclinical & Clinical Devel.", "yearBorn": 1976, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Lars  Vedin", "title": "Consultant", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 4, "compensationRisk": 10, "shareHolderRightsRisk": 1, "overallRisk": 8, "governanceEpochDate": 1682899200, "maxAge": 86400}}], "error": null}}